A few random thoughts, as long as I'm here (this is stuff you prolly already knew)...Lannett produces generic drugs, and markets them under both their own name and other private labels.Lannett is a well-established company in the Philadelphia area, but has recently undergone a rebirth of sorts, taking on new management and a new, more aggressive business plan. The new management works for reasonable salaries (IMHO), and buys and owns stock. They're a small cap. Last year, they moved from the OTC:BB to the AMEX. Lannett scores very favorably under the Foolish-8 criteria, and Investor's Business Daily has recently written them up as a result of their very high relative strength score (although RS is a fickle indicator, IMHO)Small float makes for big (potential) volatility.Lannett no longer produces the controversial diet supplement ephedrine (sp?), associated with the death of Baltimore Orioles pitcher Steve Bechler earlier this year.The population is aging while health care costs are rising. Both good for generic drug manufacturers, n'est-ce pas?Generic phharmaceuticals is an extremely competitive industry.Small caps are dicey -- they can soar quickly or flounder quickly.We're still in a bear market.I look forward to a Foolish discussion of this security!
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M